IMUX Stock Overview A biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Immunic, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Immunic Historical stock prices Current Share Price US$1.10 52 Week High US$2.11 52 Week Low US$0.97 Beta 1.88 1 Month Change -9.09% 3 Month Change -21.43% 1 Year Change -14.06% 3 Year Change -90.72% 5 Year Change -88.46% Change since IPO -95.44%
Recent News & Updates
New minor risk - Market cap size Nov 15
Independent Director recently bought US$100k worth of stock Nov 14
No longer forecast to breakeven Nov 11
Immunic, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31
We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate Oct 25
Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis Oct 22 See more updates
New minor risk - Market cap size Nov 15
Independent Director recently bought US$100k worth of stock Nov 14
No longer forecast to breakeven Nov 11
Immunic, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31
We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate Oct 25
Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis Oct 22
Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial ofidofludimus Calcium in Patients with Post COVID Syndrome Sep 04
Price target decreased by 13% to US$11.90 Aug 27
New major risk - Financial position Aug 27
New minor risk - Share price stability Aug 19
New minor risk - Profitability Aug 11
No longer forecast to breakeven Aug 11
New major risk - Financial position Aug 09
Immunic, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Immunic, Inc. Appoints Simona Skerjanec as Member of the Board Jul 24
Immunic, Inc. Appoints Jason Tardio as Chief Operating Officer and President Jul 09
New minor risk - Profitability May 09
No longer forecast to breakeven May 09
Immunic, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation Apr 30
Immunic, Inc., Annual General Meeting, Jun 11, 2024 Apr 24
Price target decreased by 32% to US$9.00 Feb 22
Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024 Feb 16
New major risk - Shareholder dilution Jan 25
Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation Jan 22 Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P. Jan 05
Forecast to breakeven in 2026 Dec 31
New major risk - Financial position Nov 17
Immunic, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Nov 08
Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts Nov 03
Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 Oct 16
Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely Oct 13
Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Oct 10
Immunic, Inc. Completes Enrollment of Its Phase 2 CallIPER Trial ofidofludimus Calcium in Progressive Multiple Sclerosis Aug 18
New major risk - Share price stability Jul 30
Immunic, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely? Jun 27
Immunic, Inc. to Report Q1, 2023 Results on May 11, 2023 May 10
Immunic, Inc. Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders May 05
High number of new directors May 01
Price target decreased by 15% to US$18.00 Feb 23
Immunic, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 17
Independent Director recently bought US$103k worth of stock Dec 16
Immunic, Inc Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential Nov 18
High number of new directors Nov 16
Price target decreased to US$21.17 Nov 06
Price target decreased to US$21.17 Nov 05
Immunic, Inc. Provides Impairment Guidance for the Quarter Ending December 31, 2022 Nov 04
Immunic, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Price target increased to US$28.75 Oct 22
Immunic, Inc. Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate Oct 21
Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo Oct 20 Immunic, Inc. announced that it expects to receive $59.949037 million in funding from a group of investors Oct 11
Immunic stock gains on $60M oversubscribed PIPE financing Oct 10
Immunic, Inc Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects Sep 21
Immunic, Inc. Receives Notice of Allowance for Composition-Of-Matter Patent in the United States for IMU-856, A Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium Aug 18
Price target decreased to US$22.40 Aug 08
Immunic GAAP EPS of -$0.72 in-line Aug 04
Immunic, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely Jul 27
Immunic, Inc. Announces Executive Changes Jul 07 Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2000 Dynamic Index
Immunic, Inc. Announces Publication of Data From its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology Jun 16
Immunic, Inc. Reports Top-Line Data from Phase 2 Caldose-1 Trial of Vidofludimus Calcium in Patients with Moderate-To-Severe Ulcerative Colitis Jun 03
Price target decreased to US$49.43 May 18
Executive Chairman recently bought US$50k worth of stock May 14
Immunic, Inc. Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease May 06
Immunic, Inc. to Report Q1, 2022 Results on May 10, 2022 May 04
High number of new directors Apr 27
Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth? Apr 13
Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis Feb 19
Immunic, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022 Feb 18
Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth? Dec 24
Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of Its Phase I Clinical Trial of IMU-935 Dec 15
Immunic, Inc. Announces Enrollment of the First Patient in Its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer Dec 10
Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation Aug 13
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis Jul 02 Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2500 Growth Index
Executive Chairman recently bought US$51k worth of stock May 13
We're Hopeful That Immunic (NASDAQ:IMUX) Will Use Its Cash Wisely May 10
Immunic EPS misses by $0.95 May 06
New 90-day low: US$14.80 Mar 05
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis Feb 19
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial Feb 18
New 90-day high: US$20.50 Feb 10
Iimmunic, Inc. Announces the Formation of a Scientific-Medical Advisory Board Nov 18
Immunic EPS misses by $0.07 Nov 05
Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19 Nov 05
Enrollment underway in Immunic's Phase 2 part of IMU-838 study in COVID-19 Nov 02
Immunic (IMUX) Investor Presentation - Slideshow Oct 31 Shareholder Returns IMUX US Biotechs US Market 7D 0% -0.1% -0.5% 1Y -14.1% -6.4% 23.2%
See full shareholder returns
Return vs Industry: IMUX underperformed the US Biotechs industry which returned -7% over the past year.
Return vs Market: IMUX underperformed the US Market which returned 23% over the past year.
Price Volatility Is IMUX's price volatile compared to industry and market? IMUX volatility IMUX Average Weekly Movement 9.3% Biotechs Industry Average Movement 11.1% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.2%
Stable Share Price: IMUX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMUX's weekly volatility (9%) has been stable over the past year.
About the Company Founded Employees CEO Website 2016 85 Daniel Vitt imux.com
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.
Show more Immunic, Inc. Fundamentals Summary How do Immunic's earnings and revenue compare to its market cap? IMUX fundamental statistics Market cap US$99.09m Earnings (TTM ) -US$96.90m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IMUX income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$96.90m Earnings -US$96.90m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 04:38 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Immunic, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution George Farmer BMO Capital Markets Equity Research William Wood B. Riley Securities, Inc. Tyler Bussian Brookline Capital Markets
Show 9 more analysts 
